Stanford’s Human Motor Control and Neuromodulation Lab is seeking those with Parkinson’s disease (PD) who already have the Medtronic Percept PC deep brain stimulation (DBS) system to participate in the ADAPT-PD clinical trial. ADAPT-PD stands for Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease. The trial is testing the use of adaptive DBS — a mode that adjusts or adapts DBS therapy automatically based on certain brain signals.
The ADAPT-PD trial aims to evaluate the safety and effectiveness of adaptive deep brain stimulation (aDBS) for Parkinson’s disease (PD).
The Medtronic Percept PC DBS system currently delivers DBS therapy in what is called continuous DBS (cDBS). In cDBS, the DBS system remains on all the time, at a constant level until it is manually adjusted by a physician.
The ADAPT-PD trial is focused on aDBS. Two modes of aDBS will be tested in this study — Single Threshold and Dual Threshold.
- In Single Threshold mode, when the aDBS software measures the brain signals are above only one level, DBS therapy increases. If the brain signals are below that one level, DBS therapy decreases.
- In Dual Threshold mode, there are two levels. If the aDBS software measures that the brain signals are above the upper level, DBS therapy increases. If the brain signals are below the lower level, DBS therapy decreases. If the aDBS software measures that the brain signals are between the two levels, DBS therapy stays the same.
Participants for the study:
- Are at least 18 years old.
- Diagnosed with idiopathic Parkinson’s.
- Have the Medtronic Percept PC DBS system already implanted.
- Attend at least 10 scheduled research visits, lasting around 1-2 hours each, over the course of about 16 months.
For more information, contact the study coordinator:
Stanford’s ADAPT-PD Study Coordinator